Company name AVEO Pharmaceuticals, Inc.
Stock symbol AVEO
Status Under Investigation

NEW YORK, February 3, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO).  Our investigation concerns whether AVEO has violated the federal securities laws and/or engaged in other unlawful business practices.

On January 31, 2019, Boston Business Journal reported that “Aveo revealed that it won’t submit its application for FDA approval due to a recommendation from the agency gather more late-stage testing results.  Specifically, the FDA is asking for additional survival data, echoing concerns that led to the agency’s rejection of the same drug in 2013.”

On this news, AVEO’s share price fell by more than 56%, closing at $0.76 per share on January 31, 2019.

If you purchased or otherwise acquired AVEO shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

First name*

Last name*

City, state, ZIP code

Email address*

Daytime phone

Evening phone

Purchase Date

No. of Shares

Purchase Price

Purchase Date

No. of Shares

Purchase Price

Join action?

Call to provide more information: Tel: (212) 355-4648

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.